1. Home
  2. PNR vs NBIX Comparison

PNR vs NBIX Comparison

Compare PNR & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pentair plc.

PNR

Pentair plc.

HOLD

Current Price

$79.35

Market Cap

13.0B

Sector

Industrials

ML Signal

HOLD

Logo Neurocrine Biosciences Inc.

NBIX

Neurocrine Biosciences Inc.

HOLD

Current Price

$131.62

Market Cap

13.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PNR
NBIX
Founded
1966
1992
Country
United Kingdom
United States
Employees
9000
N/A
Industry
Industrial Machinery/Components
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.0B
13.2B
IPO Year
2003
1996

Fundamental Metrics

Financial Performance
Metric
PNR
NBIX
Price
$79.35
$131.62
Analyst Decision
Buy
Strong Buy
Analyst Count
16
22
Target Price
$109.73
$180.91
AVG Volume (30 Days)
1.6M
1.1M
Earning Date
04-28-2026
05-05-2026
Dividend Yield
1.34%
N/A
EPS Growth
5.88
41.95
EPS
1.05
4.67
Revenue
N/A
$161,626,000.00
Revenue This Year
$4.24
$24.73
Revenue Next Year
$4.82
$13.14
P/E Ratio
$77.37
$28.21
Revenue Growth
N/A
977.51
52 Week Low
$79.49
$108.47
52 Week High
$113.95
$160.18

Technical Indicators

Market Signals
Indicator
PNR
NBIX
Relative Strength Index (RSI) 28.60 53.32
Support Level N/A $124.62
Resistance Level $91.13 $135.30
Average True Range (ATR) 2.55 3.41
MACD -1.04 0.17
Stochastic Oscillator 1.06 70.73

Price Performance

Historical Comparison
PNR
NBIX

About PNR Pentair plc.

Pentair is a global leader in the water treatment industry, with 10,000 employees and a presence in 25 countries. Its business is organized into three segments: pool, water technologies, and flow. The company offers a wide range of water solutions, including energy-efficient swimming pool equipment, filtration solutions, and commercial and industrial pumps. Pentair generated approximately $4.2 billion in revenue in 2025.

About NBIX Neurocrine Biosciences Inc.

Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.

Share on Social Networks: